Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Other Operating Expenses (2021 - 2025)

Aligos Therapeutics' Other Operating Expenses history spans 5 years, with the latest figure at $750000.0 for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 30.89% year-over-year to $750000.0; the TTM value through Dec 2025 reached $3.9 million, down 11.81%, while the annual FY2025 figure was $3.9 million, 10.99% down from the prior year.
  • Other Operating Expenses reached $750000.0 in Q4 2025 per ALGS's latest filing, down from $1.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.6 million in Q1 2024 to a low of -$225000.0 in Q2 2021.
  • Average Other Operating Expenses over 5 years is $677650.0, with a median of $797500.0 recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: crashed 104.5% in 2022, then soared 20140.0% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $176000.0 in 2021, then skyrocketed by 380.11% to $845000.0 in 2022, then crashed by 71.12% to $244000.0 in 2023, then soared by 134.84% to $573000.0 in 2024, then skyrocketed by 30.89% to $750000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Other Operating Expenses are $750000.0 (Q4 2025), $1.1 million (Q3 2025), and $1.2 million (Q2 2025).